Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
Calidi Biotherapeutics will present new data on its RedTail virotherapy platform at the AACR Annual Meeting 2026, highlighting its novel approach to simultaneously activate T-cells and induce high expression of T-cell engagers specifically in the tumor microenvironment. The company’s lead candidate, CLD-401, targets multiple solid tumors and is pro…